Clinical trials: Solid Tumor, Unspecified, Adult
Unspecified Adult Solid Tumor, Protocol Specific
A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors
The purpose of this study is to determine the side effects and best weekly dose of PR104 in patients with advanced solid tumors.
- Trial name
- NCT01358227
- Testing
- PR104
- Where
- 2 sites in New Zealand
- Volunteers
- 26 people
- Sponsor
- Proacta, Incorporated
Solid Tumor, Unspecified, Adult
A Study to Evaluate the Safety and Tolerability of AB154 in Participants With Advanced Malignancies
This is a Phase 1, multicenter, open-label, dose-escalation study to evaluate the safety, tolerability, PK, PD, and clinical activity of domvanalimab (AB154) as monotherapy and in combination with zimberelimab (AB122) in…
- Trial name
- NCT03628677
- Testing
- Domvanalimab, Zimberelimab
- Where
- 10 sites in United States, Australia
- Volunteers
- 75 people
- Sponsor
- Arcus Biosciences, Inc.
Unspecified Adult Solid Tumor, Protocol Specific
Radiation Therapy and Sargramostim in Treating Patients With Advanced Solid Tumors
RATIONALE: Colony-stimulating factors such as sargramostim increase the number of immune cells found in bone marrow or peripheral blood. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00091052
- Testing
- sargramostim, radiation therapy
- Where
- United States
- Sponsor
- Sirius Medicine
Unspecified Adult Solid Tumor, Protocol Specific
BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of BMS-247550 in treating patients who have advanced solid…
- Trial name
- NCT00004927
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Sponsor
- R-Pharm
Unspecified Adult Solid Tumor, Protocol Specific
PR-104 in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as PR-104, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00349167
- Testing
- PR-104, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Proacta, Incorporated
Unspecified Adult Solid Tumor, Protocol Specific
Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as soblidotin and gemcitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00072228
- Testing
- gemcitabine, soblidotin, chemotherapy
- Where
- 2 sites in United States
- Sponsor
- Daiichi Pharmaceuticals
Unspecified Adult Solid Tumor, Protocol Specific
An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function
This is an open-label non-randomized study in subjects with advanced or metastatic solid tumors who are no longer responding to available therapy. HALAVEN will be administered to subjects on Days 1 and 8 of a 21-day cycle.
- Trial name
- NCT01418677
- Testing
- E7389
- Where
- 9 sites in United States
- Volunteers
- 19 people
- Sponsor
- Eisai Inc.
Cancer, Solid Tumor, Adult
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Advanced Solid Tumors
Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab.
- Conditions
- Cancer, Solid Tumor, Adult, Cancer Metastatic, Solid Carcinoma
- Trial name
- KEYNOTE-E12 (NCT04443088)
- Testing
- INV-1120, Pembrolizumab
- Where
- 3 sites in United States
- Volunteers
- 78 people
- Sponsor
- Shenzhen Ionova Life Sciences Co., Ltd.
Hypercalcemia of Malignancy, Lung Cancer
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
RATIONALE: Zoledronate may help to relieve some of the symptoms caused by bone metastases. It is not yet known if zoledronate is more effective than no further therapy in relieving symptoms of bone metastases or preventing…
- Conditions
- Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain
- Trial name
- NCT00003884
- Testing
- zoledronic acid, quality-of-life assessment
- Where
- 55 sites in United States
- Volunteers
- 600 people
- Sponsor
- Novartis
Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor
Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients
This is an open label, dose finding, phase Ib clinical trial to determine the maximum tolerated dose (MTD) and/or RP2D of the orally administered PI3K/mTOR inhibitor BEZ235 in combination with the MEK1/2 inhibitor MEK162.
- Trial name
- NCT01337765
- Testing
- BEZ235 + MEK162
- Where
- 6 sites in United States, Australia and 3 more
- Volunteers
- 29 people
- Sponsor
- Pfizer
Unspecified Adult Solid Tumor, Protocol Specific
Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of intoplicine in treating patients who have advanced or…
- Trial name
- NCT00003713
- Testing
- intoplicine
- Where
- 3 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Genzyme, a Sanofi Company
Mucositis, Pain
Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis
This was an open-label, single-dose study to assess the safety, tolerability, and absorption/distribution kinetics of a single 100 µg dose of fentanyl sublingual spray in opioid-tolerant cancer subjects, with or without oral…
- Conditions
- Mucositis, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00956254
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- INSYS Therapeutics Inc
Unspecified Adult Solid Tumor, Chemotherapy
Irinotecan in Treating Patients With Refractory Solid Tumors and Liver Dysfunction
Drugs used in chemotherapy us different ways to stop tumor cells from dividing so they stop growing or die. Irinotecan may be effective in treating patients with refractory solid tumors and liver dysfunction.
- Conditions
- Unspecified Adult Solid Tumor, Chemotherapy, Liver Dysfunction, Neoplasms, Solid Tumor
- Trial name
- NCT00037804
- Testing
- Irinotecan
- Where
- 4 sites in United States
- Sponsor
- Pfizer
Lymphoma, Small Intestine Cancer
VNP40101M in Treating Patients With Advanced or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of VNP40101M in treating patients who have advanced or…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00049699
- Testing
- laromustine
- Where
- 3 sites in United States
- Sponsor
- Vion Pharmaceuticals
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the tumor. PURPOSE: This phase I trial is studying the side effects and best dose of intravenous VEGF Trap in treating…
- Trial name
- NCT00083213
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Solid Tumor, Adult, Tumor, Solid
AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to evaluate the safety and tolerability of AD1208 to determine the maximum tolerated dose(MTD) or maximumly administered dose(MAD) in any progressive, locally advanced (unresectable) or…
- Conditions
- Solid Tumor, Adult, Tumor, Solid, Solid Tumor, Solid Tumor, Unspecified, Adult
- Trial name
- AD1208 (NCT06911333)
- Testing
- AD1208
- Where
- 3 sites in South Korea
- Volunteers
- 36 people
- Sponsor
- Avelos Therapeutics Inc.
Unspecified Adult Solid Tumor, Protocol Specific
SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of SR-45023A in treating patients who have locally advanced…
- Trial name
- NCT00004049
- Testing
- apomine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Genzyme, a Sanofi Company
Cancer
Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Intravenous VEGF Trap may stop the growth of solid tumors or non-Hodgkin's lymphoma by stopping blood flow to the cancer.
- Trial name
- NCT00082823
- Testing
- ziv-aflibercept
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Regeneron Pharmaceuticals
Unspecified Adult Solid Tumor, Protocol Specific
DJ-927 and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as DJ-927 and capecitabine, use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00077077
- Testing
- DJ-927, capecitabine
- Where
- 3 sites in United States
- Sponsor
- Daiichi Sankyo
Non-colorectal Cancer, Pancreatic Cancer
Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors
RATIONALE: Monoclonal antibodies, such as maytansinoid DM4-conjugated humanized monoclonal antibody huC242, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00352131
- Testing
- HuC242-DM4
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- ImmunoGen, Inc.